References
Rowe JM (2009) Optimal induction and post-remission therapy for AML in first remission. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program:396-405. doi:10.1182/asheducation-2009.1.396
Kaspers GJ, Zwaan CM (2007) Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 92(11):1519–1532
Galmarini CM, Thomas X, Graham K, El Jafaari A, Cros E, Jordheim L, Mackey JR, Dumontet C (2003) Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol 122(1):53–60
Cohen SS (1976) The lethality of aranucleotides. Med Biol 54(5):299–326
Abraham A, Varatharajan S, Abbas S, Zhang W, Shaji RV, Ahmed R, George B, Srivastava A, Chandy M, Mathews V, Balasubramanian P (2012) Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Pharmacogenomics 13(3):269–282. doi:10.2217/pgs.11.149
Braess J, Pfortner J, Kern W, Hiddemann W, Schleyer E (1999) Cytidine deaminase—the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells. Ann Hematol 78(11):514–520
Ciccolini J, Dahan L, Andre N, Evrard A, Duluc M, Blesius A, Yang C, Giacometti S, Brunet C, Raynal C, Ortiz A, Frances N, Iliadis A, Duffaud F, Seitz JF, Mercier C (2010) Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol 28(1):160–165
Mercier C, Raynal C, Dahan L, Ortiz A, Evrard A, Dupuis C, Blesius A, Duluc M, Franceschini F, Giacometti S, Salas S, Milano G, Favre R, Seitz JF, Ciccolini J (2007) Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics 17(10):841–844
Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM (2009) Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol 144(3):388–394. doi:10.1111/j.1365-2141.2008.07461.x
Forghieri F, Luppi M, Morselli M, Potenza L (2007) Cytarabine-related lung infiltrates on high resolution computerized tomography: a possible complication with benign outcome in leukemic patients. Haematologica 92(9):e85–90
Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, Ravindranath Y, Matherly LH, Taub JW (2004) The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res 64(2):728–735
Acknowledgments
The authors would like to thank the Department of Biotechnology, India for the financial assistance given to the principal investigator PB (Grant no: BT/01/COE/08/03). AA and SK are recipients of fellowship from University Grants Commission (UGC), India. VM is supported by the Wellcome-DBT senior fellowship program.
Conflict of interest
The authors have no conflicts of interest to disclose.
Author contributions
AA performed the research, analyzed the data, and wrote the paper. AJD performed the clinical data accrual, analyzed the data, and wrote the paper. SV performed the research. SK performed the research. PB was the principal investigator, designed the study, performed the research, analyzed the data, and wrote the paper. VM performed the clinical data accrual, analyzed the data, and wrote the paper.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abraham, A., Devasia, A.J., Varatharajan, S. et al. Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia. Ann Hematol 94, 883–885 (2015). https://doi.org/10.1007/s00277-014-2254-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-014-2254-2